Tildacerfont is a medication being studied for its potential to help people with a condition called congenital adrenal hyperplasia. This condition affects the adrenal glands, which are small organs on top of the kidneys that produce important hormones. People with this condition often need to take high doses of medications called glucocorticoids to manage their symptoms. Tildacerfont is being tested to see if it can reduce the need for these high doses, which can have side effects. The goal is to find out if Tildacerfont can help patients use lower doses of glucocorticoids while still keeping their condition under control.

Classic Congenital Adrenal Hyperplasia – Classic Congenital Adrenal Hyperplasia is a genetic disorder affecting the adrenal glands, which are responsible for producing certain hormones. This condition leads to a deficiency in enzymes needed for hormone production, resulting in an imbalance of hormones such as cortisol and aldosterone. As the disease progresses, individuals may experience symptoms like early puberty, rapid growth during childhood but shorter than average height in adulthood, and ambiguous genitalia in females. The lack of cortisol can also lead to an overproduction of androgens, causing further hormonal imbalances. Over time, the body may struggle to maintain normal blood pressure, blood sugar levels, and respond to stress effectively. The condition is present from birth and requires ongoing management to address hormone imbalances.